Christopher Hagenstad

1.7k total citations · 1 hit paper
14 papers, 847 citations indexed

About

Christopher Hagenstad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Christopher Hagenstad has authored 14 papers receiving a total of 847 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Christopher Hagenstad's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). Christopher Hagenstad is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). Christopher Hagenstad collaborates with scholars based in United States, Germany and Hungary. Christopher Hagenstad's co-authors include Allen Lee Cohn, Tarek Chidiac, Rafael G. Amado, Robert G Deeter, Edith P. Mitchell, Seta Shahin, David R. Spigel, John L. Marshall, David McCollum and J. Randolph Hecht and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Christopher Hagenstad

14 papers receiving 823 citations

Hit Papers

A Randomized Phase IIIB T... 2008 2026 2014 2020 2008 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
    2008 644 citations J. Randolph Hecht, Edith P. Mitchell et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Hagenstad United States 8 687 297 198 168 149 14 847
Seta Shahin United States 8 812 1.2× 319 1.1× 186 0.9× 120 0.7× 145 1.0× 13 948
B. Nelson United States 7 795 1.2× 278 0.9× 199 1.0× 295 1.8× 92 0.6× 12 1.0k
Tarek Chidiac United States 11 802 1.2× 384 1.3× 187 0.9× 207 1.2× 137 0.9× 16 1.0k
A. Misino Italy 11 755 1.1× 368 1.2× 221 1.1× 134 0.8× 106 0.7× 25 983
Roger Sidhu United States 13 715 1.0× 388 1.3× 152 0.8× 139 0.8× 248 1.7× 29 904
R Castan France 4 829 1.2× 392 1.3× 288 1.5× 200 1.2× 166 1.1× 6 1.0k
Vicente Alonso-Orduña Spain 7 832 1.2× 402 1.4× 261 1.3× 143 0.9× 140 0.9× 23 1.0k
Claus-Christoph Steffens Germany 7 972 1.4× 481 1.6× 310 1.6× 148 0.9× 164 1.1× 18 1.1k
E.U. Steinhauer Germany 6 860 1.3× 370 1.2× 196 1.0× 116 0.7× 145 1.0× 10 982
Federico Nasroulah United States 11 824 1.2× 395 1.3× 190 1.0× 206 1.2× 153 1.0× 29 993

Countries citing papers authored by Christopher Hagenstad

Since Specialization
Citations

This map shows the geographic impact of Christopher Hagenstad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Hagenstad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Hagenstad more than expected).

Fields of papers citing papers by Christopher Hagenstad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Hagenstad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Hagenstad. The network helps show where Christopher Hagenstad may publish in the future.

Co-authorship network of co-authors of Christopher Hagenstad

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Hagenstad. A scholar is included among the top collaborators of Christopher Hagenstad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Hagenstad. Christopher Hagenstad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Sharman, Jeff P., Andrei R. Shustov, Mitchell R. Smith, et al.. (2015). Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. Blood. 126(23). 1744–1744. 3 indexed citations
3.
4.
Bendell, Johanna C., John Nemunaitis, S. Vukelja, et al.. (2011). Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 29(33). 4394–4400. 81 indexed citations
5.
6.
7.
Hurvitz, Sara A., Heather Allen, Rebecca Moroose, et al.. (2010). A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). Clinical Breast Cancer. 10(4). 307–312. 7 indexed citations
8.
9.
Hurvitz, Sara A., Mark D. Pegram, David W. Chan, et al.. (2009). Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.. Cancer Research. 69(24_Supplement). 6094–6094. 37 indexed citations
10.
Vukelja, S., Donald Richards, Luis T. Campos, et al.. (2009). Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer. Journal of Clinical Oncology. 27(15_suppl). 4081–4081. 8 indexed citations
11.
Hurvitz, Sara A., Heather Allen, R Moroose, et al.. (2008). Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01). European Journal of Cancer Supplements. 6(7). 217–217. 1 indexed citations
12.
Hecht, J. Randolph, Edith P. Mitchell, Tarek Chidiac, et al.. (2008). A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer. Journal of Clinical Oncology. 27(5). 672–680. 644 indexed citations breakdown →
13.
Hagenstad, Christopher, et al.. (2006). A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 7127–7127. 13 indexed citations
14.
Hagenstad, Christopher, Scott E. Kilpatrick, Mark J. Pettenati, & Paul D. Savage. (2003). Inflammatory Myofibroblastic Tumor With Bone Marrow Involvement. Archives of Pathology & Laboratory Medicine. 127(7). 865–867. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seta Shahin Breakdown of academic impact, for papers by B. Nelson Breakdown of academic impact, for papers by Tarek Chidiac Breakdown of academic impact, for papers by A. Misino Breakdown of academic impact, for papers by Roger Sidhu Breakdown of academic impact, for papers by R Castan Breakdown of academic impact, for papers by Vicente Alonso-Orduña Breakdown of academic impact, for papers by Claus-Christoph Steffens Breakdown of academic impact, for papers by E.U. Steinhauer Breakdown of academic impact, for papers by Federico Nasroulah
Rankless by CCL
2026